According to filings with the U.S. Securities and Exchange Commission, BiVACOR is raising $36,000,000.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Tom Vassiliades played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About BiVACOR
BiVACOR is a privately held company that was founded in 2008. Our world headquarters is located in Houston, Texas, USA with an international office in Brisbane, Australia. A contingent of highly qualified staff are working diligently toward the development of this ground breaking technology. They include highly experienced and world class engineers, medical specialists and business executives. Together they have set up a strong collaborative network which branches out both nationally and internationally. Developer of an artificial heart-pumping device designed to take over the complete function of a patients failing heart. The companys compact device comprises a magnetically levitated rotor located between opposing pump casings and leverages rotary blood pump technology to provide the required cardiac output, enabling patients to reduce the risk of blood-cell damage and clotting, therefore, surviving with a substitute blood pumping system. According to the US National Institutes of Health (NIH), 100,000 patients could immediately benefit from a ventricular assist device (VAD) or total artificial heart (TAH), and the European market is similarly sized. Without intervention, patients with severe HF have a bleak outlook. For these patients, drug therapy is a limited, relatively ineffective option. Although a heart transplant would meet their needs, only 4000 donor hearts are available globally each year. The BiVACOR TAH is designed to be a long-term device that can replace the total function of the patients native heart. The small, compact device uses proven rotary blood-pump technology to provide the required cardiac output. The BiVACOR system comprises a magnetically levitated rotor located between opposing pump casings. The key feature that enables this device to support both the left and right sides of the heart is the left and right impeller blades, which are mounted on either side of the rotating hub. The hub is levitated and rotated via an electromagnetic motor and bearing arrangement on top of the pump casings. The dedicated hydraulic design of the impellers, combined with state-of-the-art magnetic levitation (MAGLEV) technology, permits control of the circulation to be fine-tuned by means of a differential fluid output.

To learn more about BiVACOR, visit http://www.bivacor.com/

Contact:
Tom Vassiliades, Chief Executive Officer
562-732-4272
https://www.linkedin.com/in/vassiliades/

SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.